MK 3475-689 – A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Standard of Care as Adjuvant Therapy for Stage III-IVB Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)

Identifizierung von funktionellen Biomarkern für Tinnitus und Hyperakusis im Tiermodell und Menschen

NIS-HANNA – A National, Prospective, Non-Interventional Study (NIS) of Nivolumab in Patients with Squamous Cell Carcinom of the Head and Neck (SCCHN) progressing on or After Platinum-Based Therapy.

Big data approaches to identify novel hearing loss genes

Sensorion – SENS-401-201

MK 3475 - 669 – A Phase III Randomized, Open-Label Clinical Study to Evaluate the Efficacy and Safety of Pembrolizumab plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen as First line Treatment for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Effect of Mepolizumab in severe nasal polyps